|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference显示文摘 | Jordi Bruix Morris Sherman Josep M Llovet Michel Beaugrand Riccardo Lencioni Andrew K Burroughs Erik Christensen Luigi Pagliaro Massimo Colombo Juan Rodés | 2001 | Journal of Hepatology2001，，3： | 11 |
| 2 | Statements from the Taormina expert meeting on occult hepatitis B virus infection显示文摘 | Giovanni Raimondo Jean-Pierre Allain Maurizia R. Brunetto Marie-Annick Buendia Ding-Shinn Chen Massimo Colombo Antonio Craxì Francesco Donato Carlo Ferrari Giovanni B. Gaeta Wolfram H. Gerlich Massimo Levrero Stephen Locarnini Thomas Michalak Mario U. Mon | 2008 | Journal of Hepatology2008，，4： | 5 |
| 3 | Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies显示文摘Hepatocellular carcinoma (HCC) develops in the context of environmental risk factors like chronic viral hepatitis, diabetes and alcohol exposure, often associated to an increased risk of cirrhosis. Antiviral treatments that are effective to counteract hepatitis B and C may also attenuate the risk of tumor development. However, since hepatitis B-related carcinogenesis is promoted independently of the onset of cirrhosis, such antiviral treatments as nucleo(t)side analogs can promote regression of cirrhosis, prevent clinical decompensation and variceal bleeding but not HCC. This means that in successfully treated patients with cirrhosis, HCC is often the consequence of their extended survival. In hepatitis C patients, a sustained virological response to interferon-based therapies can reduce the rate of HCC development, even in patients with cirrhosis who experience histological regression of their liver disease. Future therapies aimed at this endpoint in at risk populations should take into consideration pretreatment patient stratification for host, viral and environmental risk factors. In this context the recent discovery of single nucleotide polymorphisms involved in the immune system function and tumorigenesis, might permit enrollment of populations of patients enriched with HCC risk factors for targeted chemopreventive therapies. This could finally pave the way to personalized algorithms, as already seen in the diagnosis and treatment schemes for chemoprevention. | Cristina Della Corte Alessio Aghemo Massimo Colombo | 2013 | World Journal of Gastroenterology2013，19，9： | 4 |
| 4 | Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues显示文摘 | Carolina Boni Diletta Laccabue Pietro Lampertico Tiziana Giuberti Mauro Viganò Simona Schivazappa Arianna Alfieri Marco Pesci Giovanni B. Gaeta Giuseppina Brancaccio Massimo Colombo Gabriele Missale Carlo Ferrari | 2012 | Gastroenterology2012，，4： | 3 |
| 5 | Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study显示文摘 | Joong‐Won Park Minshan Chen Massimo Colombo Lewis R. Roberts Myron Schwartz Pei‐Jer Chen Masatoshi Kudo Philip Johnson Samuel Wagner Lucinda S. Orsini Morris Sherman | 2015 | Liver Int2015，，9： | 3 |
| 6 | Founders’ human capital and the growth of new technology-based firms: A competence-based view显示文摘 | Massimo G. Colombo Luca Grilli | 2005 | Research Policy2005，，6： | 3 |
| 7 | Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C显示文摘 | Mirella Fraquelli Cristina Rigamonti Giovanni Casazza Maria Francesca Donato Guido Ronchi Dario Conte Mariagrazia Rumi Pietro Lampertico Massimo Colombo | 2010 | Journal of Hepatology2010，，4： | 3 |
| 8 | A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma显示文摘 | Raffaella Romeo Ersilio Del Ninno Mariagrazia Rumi Antonio Russo Angelo Sangiovanni Roberto de Franchis Guido Ronchi Massimo Colombo | 2009 | Gastroenterology2009，，5： | 2 |
| 9 | Surveillance for Hepatocellular Carcinoma显示文摘 | Cristina Della Corte Massimo Colombo | 2012 | Seminars in Oncology2012，，4： | 2 |
| 10 | A review of the treatment of chronic hepatitis C virus infection in cirrhosis显示文摘 | Elena Vezali Alessio Aghemo Massimo Colombo | 2010 | Clinical Therapeutics2010，，13： | 2 |
| 11 | Swelling and drug release in hydrogel matrices: polymer viscosity and matrix porosity effects 显示文摘 | Bettni R Colombo P Massimo G | 1994 | Eur J Pharm Sci1994，2，3： | 2 |
| 12 | ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection显示文摘 | Pietro Andreone Massimo G. Colombo Jeffrey V. Enejosa Iftihar Koksal Peter Ferenci Andreas Maieron Beat Müllhaupt Yves Horsmans Ola Weiland Henk W. Reesink Lino Rodrigues Yiran B. Hu Thomas Podsadecki Barry Bernstein | 2014 | Gastroenterology2014，，： | 2 |
| 13 | Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective显示文摘 | Massimo Colombo Jean-Luc Raoul Riccardo Lencioni Peter R. Galle Jessica Zucman-Rossi Rafael Ba?ares Daniel Seehofer Peter Neuhaus Philip Johnson | 2013 | European Journal of Gastroenterology & Hepatology2013，，6： | 2 |
| 14 | Localized intra-abdominal fibromatosis of the small bowel mimicking a gastrointestinal stromal tumor: A case report显示文摘Intra-abdominal fibromatosis (IAF) is a benign mesenchymal lesion that can occur throughout the gastrointestinal tract. Although rare, it is the most common primary tumor of the mesentery and can develop at any age. We describe a rare case of primary IAF involving the mesentery and small bowel which clinically, macroscopically and histologically mimicked malignant gastrointestinal stromal tumor (GIST). This report highlights the fact that benign IAF can be misdiagnosed as a malignant GIST localized in the mesentery or arising from the intestinal wall. Their diagnostic discrimination is essential because of their very different biological behaviors and the fact that the introduction of effective therapies involving tyrosine kinase inhibitor STI571 (imatinib mesylate) has greatly changed the clinical approach to intra-abdominal stromal spindle cell tumors. | Piergiuseppe Colombo Daoud Rahal Fabio Grizzi Vittorio Quagliuolo Massimo Roncalli | 2005 | World Journal of Gastroenterology2005，11，33： | 2 |
| 15 | Liver precancerous lesions and hepatocellular carcinoma: The histology report显示文摘 | Massimo Roncalli Luigi Terracciano Luca Di Tommaso Ezio David Massimo Colombo | 2011 | Digestive and Liver Disease2011，，： | 2 |
| 16 | Internal Social Capital and the Attraction of Early Contributions in Crowdfunding显示文摘 | Massimo G. Colombo Chiara Franzoni Cristina Rossi‐Lamastra | 2015 | Entrepreneurship Theory and Practice2015，，1： | 2 |
| 17 | Y chromosome loss in male patients with primary biliary cirrhosis显示文摘 | Ana Lleo Sabine Oertelt-Prigione Ilaria Bianchi Lisa Caliari Palma Finelli Monica Miozzo Roberta Lazzari Annarosa Floreani Francesca Donato Massimo Colombo M. Eric Gershwin Mauro Podda Pietro Invernizzi | 2013 | Journal of Autoimmunity2013，，： | 2 |
| 18 | Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance显示文摘 | Angelo Sangiovanni Ersilio Del Ninno Pierangelo Fasani Cristina De Fazio Guido Ronchi Raffaella Romeo Alberto Morabito Roberto de Franchis Massimo Colombo | 2004 | Gastroenterology2004，，4： | 2 |
| 19 | Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy显示文摘 | Massimo Iavarone Giuseppe Cabibbo Fabio Piscaglia Claudio Zavaglia Antonio Grieco Erica Villa Calogero Cammà Massimo Colombo | 2011 | Hepatology2011，，6： | 2 |
| 20 | Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest?) and transient elastography (FibroScan?)显示文摘 | Thierry Poynard Julien Vergniol Yen Ngo Juliette Foucher Mona Munteanu Wassil Merrouche Massimo Colombo Vincent Thibault Eugene Schiff Clifford A. Brass Janice K. Albrecht Marika Rudler Olivier Deckmyn Pascal Lebray Dominique Thabut Vlad Ratziu Victor de | 2013 | Journal of Hepatology2013，，： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员